Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has acquired Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage technology platform for the development of ADCs. While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which includes payload and...